PMID- 36108212
OWN - NLM
STAT- MEDLINE
DCOM- 20220919
LR  - 20230328
IS  - 1538-067X (Electronic)
IS  - 1092-1095 (Print)
IS  - 1092-1095 (Linking)
VI  - 26
IP  - 5
DP  - 2022 Sep 15
TI  - Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping 
      Non-Small Cell Lung Cancer.
PG  - 543-551
LID - 10.1188/22.CJON.543-551 [doi]
AB  - BACKGROUND: Tepotinib, a highly selective, oral, once-daily MET inhibitor, has 
      been approved for treatment of metastatic MET exon 14 skipping non-small cell 
      lung cancer. OBJECTIVES: This article provides nurse-specific recommendations for 
      identification and management of tepotinib adverse events (AEs). METHODS: 
      Guidance on monitoring and proactive/reactive AE management was developed based 
      on published literature and real-world nursing experience. Case studies of VISION 
      trial participants were summarized to illustrate key principles. FINDINGS: 
      Tepotinib AEs are generally mild to moderate and manageable, and can include 
      peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. 
      Alongside supportive care, tepotinib interruption and dose reduction is 
      recommended for grade 3 AEs. For peripheral edema, proactive monitoring is 
      crucial, and treatment interruption (including frequent, short treatment 
      holidays) should be considered early. Nursing management of tepotinib AEs 
      includes proactive monitoring, patient education, and interprofessional team 
      coordination.
FAU - Ahn, Linda
AU  - Ahn L
AD  - Memorial Sloan Kettering Cancer Center.
FAU - Alexander, Terri
AU  - Alexander T
AD  - University of Texas MD Anderson Cancer Center.
FAU - Vlassak, Soetkin
AU  - Vlassak S
AD  - Global Medical Affairs, Merck N.V.-S.A.
FAU - Berghoff, Karin
AU  - Berghoff K
AD  - Merck KGaA.
FAU - Lemmens, Liesbeth
AU  - Lemmens L
AD  - COPE-unlimited.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - Clin J Oncol Nurs
JT  - Clinical journal of oncology nursing
JID - 9705336
RN  - 0 (Piperidines)
RN  - 0 (Pyridazines)
RN  - 0 (Pyrimidines)
RN  - 1IJV77EI07 (tepotinib)
RN  - AYI8EX34EU (Creatinine)
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/genetics
MH  - Creatinine
MH  - Exons
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - Piperidines
MH  - Pyridazines
MH  - Pyrimidines
PMC - PMC10034867
MID - NIHMS1809773
OTO - NOTNLM
OT  - MET exon 14 skipping
OT  - non-small cell lung cancer
OT  - peripheral edema
OT  - tepotinib
COIS- Financial disclosures: Linda Ahn has no conflicts of interest to declare. Terri 
      Alexander has no conflicts of interest to declare. Liesbeth Lemmens has no 
      conflicts of interest to declare. Soetkin Vlassak and Karin Berghoff are 
      employees of the healthcare business of Merck KGaA, Darmstadt, Germany.
EDAT- 2022/09/16 06:00
MHDA- 2022/09/20 06:00
PMCR- 2023/03/23
CRDT- 2022/09/15 15:42
PHST- 2022/09/15 15:42 [entrez]
PHST- 2022/09/16 06:00 [pubmed]
PHST- 2022/09/20 06:00 [medline]
PHST- 2023/03/23 00:00 [pmc-release]
AID - 10.1188/22.CJON.543-551 [doi]
PST - ppublish
SO  - Clin J Oncol Nurs. 2022 Sep 15;26(5):543-551. doi: 10.1188/22.CJON.543-551.